PMID: 700900Oct 15, 1978Paper

Oncogenicity of Friend-virus-infected cells: determination of origin of spleen colonies by the H-2 antigens as genetic markers

International Journal of Cancer. Journal International Du Cancer
F Wendling, P E Tambourin

Abstract

Spleen cells from mice infected with Friend leukemia virus (FLV) inoculated by the intravenous route give rise to macroscopically visible colonies in the spleens of normal F1 histocompatible hybrid hosts. A study of H-2 antigens as generic markers for identification of strains of origin of cells constituting the spleen colonies was undertaken. The standard cytotoxic test was demonstrated to be suitable for characterizing the H-2 antigens present on the surface of spleen cells from normal of FLV-leukemic parents of F1 hybrid mice. Individual colonies dissected out of the spleen of (C3HxC57B6/6) F1 recipients (H-2k/H-2b), 10 days after the intravenous graft of FLV-infected spleen cells of C3H origin (H-2k), were all sensitive to anti-C57BL/6 antibodies. In the same way, colonies obtained from the spleens of (DBA/2xC57BL/10) F1 recipients (H-2d/H-2b) grafted with DBA/2 leukemic spleen cells (H-2d) were all sensitive to both anti-H-2b and anti-H-2d antibodies. These results directly prove that the main cell population constituing a spleen colony arises from the recipient. The authors conclude that the spleen colonies do not result from the neoplastic proliferation of injected donor cells but rather from the multiplication of host c...Continue Reading

References

Jun 1, 1973·Transplantation·I F McKenzie
May 1, 1974·The Journal of Experimental Medicine·V KumarR J Eckner
Oct 1, 1972·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P Bentvelzen
May 15, 1972·International Journal of Cancer. Journal International Du Cancer·F WendlingP Jullien
Jan 1, 1973·Journal of the National Cancer Institute·G B RossiC Friend
Mar 15, 1973·International Journal of Cancer. Journal International Du Cancer·F Smadja-JoffeC Bournoutian
Oct 1, 1967·Proceedings of the National Academy of Sciences of the United States of America·G B Rossi, C Friend
Jun 1, 1967·Japanese Journal of Medical Science & Biology·H YoshikuraH Sugano
May 1, 1967·Developmental Biology·J L Curry, J J Trentin
Feb 1, 1961·Proceedings of the Society for Experimental Biology and Medicine·E A MIRANDJ T GRACE

❮ Previous
Next ❯

Citations

Jan 1, 1979·Journal of Supramolecular Structure·J E Lever
Jan 1, 1982·Journal of Cancer Research and Clinical Oncology·H J Seidel
Sep 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·W D Hankins, S B Krantz
Jun 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·F WendlingP Tambourin
Apr 1, 1979·The Journal of Experimental Medicine·D McCoolA Bernstein
Mar 16, 2006·Journal of Virology·Nicole GerlachUlf Dittmer
Jan 1, 1979·Leukemia Research·P E TambourinF Smadja-Joffe
Jan 9, 2009·European Journal of Immunology·Nicole GerlachUlf Dittmer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.